PREMPHASE 14/14 Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Premphase 14/14, and what generic alternatives are available?

Premphase 14/14 is a drug marketed by Wyeth Pharms and is included in one NDA.

The generic ingredient in PREMPHASE 14/14 is estrogens, conjugated; medroxyprogesterone acetate. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the estrogens, conjugated; medroxyprogesterone acetate profile page.

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for PREMPHASE 14/14?
What are the global sales for PREMPHASE 14/14?
What is Average Wholesale Price for PREMPHASE 14/14?

Summary for PREMPHASE 14/14

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	397
Formulation / Manufacturing:	see details
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for PREMPHASE 14/14
DailyMed Link:	PREMPHASE 14/14 at DailyMed

Drug patent expirations by year for PREMPHASE 14/14

Pharmacology for PREMPHASE 14/14

Drug Class	Estrogen Progestin
Mechanism of Action	Estrogen Receptor Agonists

US Patents and Regulatory Information for PREMPHASE 14/14

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Wyeth Pharms	PREMPHASE 14/14	estrogens, conjugated; medroxyprogesterone acetate	TABLET;ORAL-28	020527-002	Nov 17, 1995		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for PREMPHASE 14/14

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Wyeth Pharms	PREMPHASE 14/14	estrogens, conjugated; medroxyprogesterone acetate	TABLET;ORAL-28	020527-002	Nov 17, 1995	⤷ Sign Up	⤷ Sign Up
Wyeth Pharms	PREMPHASE 14/14	estrogens, conjugated; medroxyprogesterone acetate	TABLET;ORAL-28	020527-002	Nov 17, 1995	⤷ Sign Up	⤷ Sign Up
Wyeth Pharms	PREMPHASE 14/14	estrogens, conjugated; medroxyprogesterone acetate	TABLET;ORAL-28	020527-002	Nov 17, 1995	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for PREMPHASE 14/14

See the table below for patents covering PREMPHASE 14/14 around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Egypt	23687	Controlled release of steroids from sugar coatings	⤷ Sign Up
Australia	3726093		⤷ Sign Up
Australia	3140584		⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

Supplementary Protection Certificates for PREMPHASE 14/14

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0136011	SPC/GB00/025	United Kingdom	⤷ Sign Up	SPC/GB00/025: 20040802, EXPIRES: 20090801
0136011	99C0003	Belgium	⤷ Sign Up	PRODUCT NAME: ESTRADIOL AND NORETHISTERONE; FIRST REGISTRATION NO/DATE: 403 IS 106 F3 19980928; FIRST REGISTRATION: SE 14007 19980306
0136011	91096	Luxembourg	⤷ Sign Up	91096, EXPIRES: 20090802
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

AI Research Assistant

Questions you can ask:

Summary for PREMPHASE 14/14

Pharmacology for PREMPHASE 14/14

Make Better Decisions: Try a trial or see plans & pricing